Jon Congleton

Chief Executive Officer, Mineralys Therapeutics, Inc.

Search every verified Jon Congleton interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Jon Congleton, Chief Executive Officer of Mineralys Therapeutics, discussed the company's second-quarter 2026 financial results and business updates during an earnings call on August 11, 2026. He confirmed that the company's New Drug Application for lorundrostat is under FDA review with a December 2026 PDUFA target date. Congleton stated that feedback from the company's national account team has been "very bullish" regarding market access for the therapy, particularly in third- and fourth-line treatment positions, and described payer dialogues as "very positive," with rebate levels consistent with expectations. Congleton characterized aldosterone synthase inhibitors as a potentially "transformative" introduction to hypertension treatment, noting pronounced reductions in blood pressure for patients on two or more background medications who have not reached their treatment goals. He also suggested that distinct label points could create differentiation for lorundrostat and indicated that the therapy's potential role in addressing aldosterone's broader impact on cardiometabolic conditions could create opportunities to move earlier in lines of treatment.